Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Sunho Pharmaceutical Co EV-to-FCF?
Beijing Sunho Pharmaceutical CoBJSE:920017 80 EV-to-FCF is 10.85 as of Sep. 21, 2026, which is 79% above its 10-year median of 6.05. GuruFocus rates BJSE:920017 with a GF Score™ of 80/100 and a GF Value™ of ¥15.19 (Fairly Valued). The stock has 2 warning signs investors should review. Among 573 Drug Manufacturers companies, Beijing Sunho Pharmaceutical Co ranks better than 70.51% on this metric.
The historical rank and industry rank for Beijing Sunho Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
BJSE:920017'
s EV-to-FCF Range Over the Past 10 Years
Min: -266.51 Med: 6.05 Max: 31.04
Current: 11.88
During the past 10 years, the highest EV-to-FCF of Beijing Sunho Pharmaceutical Co was 31.04. The lowest was -266.51. And the median was 6.05.
BJSE:920017's EV-to-FCF is ranked better than 70.51% of 573
companies
in the Drug Manufacturers industry
Industry Median: 19.09
vs BJSE:920017: 11.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Sunho Pharmaceutical Co (BJSE:920017) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Sunho Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Beijing Sunho Pharmaceutical Co's share price for today is ¥15.67.
Beijing Sunho Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.935.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Beijing Sunho Pharmaceutical Co EV-to-FCF Related Terms
Beijing Sunho Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Sunho Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Sunho Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Sunho Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Beijing Sunho Pharmaceutical Co's EV-to-FCF falls into.
Beijing Sunho Pharmaceutical Co's current Enterprise Value is ¥1,081.0 Mil.
Beijing Sunho Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥99.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sunho Pharmaceutical Co (BJSE:920017) has a EV-to-FCF of 10.85 as of Sep. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Sunho Pharmaceutical Co and its competitors. This is 79% above median its historical median of 6.05. According to the industry distribution chart, Beijing Sunho Pharmaceutical Co ranks #169 out of 573 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Beijing Sunho Pharmaceutical Co's EV-to-FCF too high?
Beijing Sunho Pharmaceutical Co's current EV-to-FCF of 10.85 is 79% above median its 10-year median of 6.05. The Drug Manufacturers industry median EV-to-FCF is 19.09. Beijing Sunho Pharmaceutical Co's value of 10.85 is 43.2% below this industry median. Based on the distribution chart, Beijing Sunho Pharmaceutical Co ranks #169 out of 573 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beijing Sunho Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sunho Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Sunho Pharmaceutical Co ranks #169 out of 573 companies for EV-to-FCF. This puts Beijing Sunho Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 19.09. Beijing Sunho Pharmaceutical Co's value of 10.85 is 43.2% below this benchmark. While the company's 10-year median is 6.05 vs. the industry median of 19.09, Beijing Sunho Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.09, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Sunho Pharmaceutical Co's current EV-to-FCF of 10.85 is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Sunho Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Sunho Pharmaceutical Co's current EV-to-FCF is 10.85, which is 79% above median its own 10-year median of 6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sunho Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co (BJSE:920017) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.19, compared to a current price of ¥15.67 — trading 3.2% above its estimated fair value. The current EV-to-FCF is 10.85, which is 79% above median its 10-year median of 6.05 and 43.2% below the Drug Manufacturers industry median of 19.09. Beijing Sunho Pharmaceutical Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Beijing Sunho Pharmaceutical Co (BJSE:920017), the current EV-to-FCF is 10.85 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Sunho Pharmaceutical Co (BJSE:920017) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.67 is trading 3.2% above its estimated GF Value™ of ¥15.19.
GuruFocus considers Beijing Sunho Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920017:
EV-to-FCF: 10.85 (79% above median its 10-year median of 6.05)
GF Value™: ¥15.19 vs. price of ¥15.67 (3.2% above fair value)
Industry Position: 43.2% below the Drug Manufacturers median (#169 of 573)
No single metric tells the full story. See the BJSE:920017 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Sunho Pharmaceutical Co Ltd engages in the research and development, production, and sales of pharmaceutical preparations while providing CMC/CMO integrated services for pharmaceutical preparation manufacturers and drug R&D enterprises. The company produces small-volume injections, freeze-dried powder injections, hard capsules, tablets, and other products. The company's main products included: compound digestive enzyme capsules, piracetam (small injection and powder injection), and oxalic acid acetate.
80GF Score
Get the complete analysis for BJSE:920017
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920017 has been successfully added to your 
